Q-linea AB (OSTO:QLINEA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:QLINEA Q-linea AB OSTO:QLINEA
66 GF Score
Price kr17.55
GF Value kr19.37
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Q-linea AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

OSTO:QLINEA
66GF Score
Q-linea AB OSTO:QLINEA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Q-linea AB (OSTO:QLINEA) Overvalued in 2026?

Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued. The current stock price of kr17.55 is trading 9.4% below its estimated GF Value™ of kr19.37. GuruFocus considers Q-linea AB to be Fairly Valued.

Key valuation signals for OSTO:QLINEA:

  • Dividends Received:
  • GF Value™: kr19.37 vs. price of kr17.55 (9.4% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the OSTO:QLINEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Q-linea AB Business Description

Other Exchanges 3F80:Germany
Address Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
66GF Score

Get the complete analysis for OSTO:QLINEA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.55
Price
kr19.37
GF Value